PT  - JOURNAL ARTICLE
AU  - Guillamet, M Cristina Vazquez
AU  - Guillamet, Rodrigo Vazquez
AU  - Kramer, Andrew A.
AU  - Maurer, Paula M.
AU  - Menke, Gregory A.
AU  - Hill, Cherie L.
AU  - Knaus, William A.
TI  - TOWARD A COVID-19 SCORE-RISK ASSESSMENTS AND REGISTRY
AID  - 10.1101/2020.04.15.20066860
DP  - 2020 Jan 01
TA  - medRxiv
PG  - 2020.04.15.20066860
4099  - http://medrxiv.org/content/early/2020/04/20/2020.04.15.20066860.short
4100  - http://medrxiv.org/content/early/2020/04/20/2020.04.15.20066860.full
AB  - Importance Critical care resources like ventilators, used to manage the current COVID-19 pandemic, are potentially inadequate. Established triage standards and guidelines may not contain the most appropriate severity assessment and outcome prediction models.Objectives Develop a draft pandemic specific triage assessment score for the current COVID-19 pandemic. Design a website where initial Toward a COVID-19 Scores (TACS) can be quickly calculated and used to compare various treatment strategies. Create a TACS Registry where data and outcomes for suspected and confirmed COVID-19 patients can be recorded. Use the TACS Registry to develop an influenza epidemic specific database and score for use in future respiratory based epidemics.Design, Setting, Participants Retrospective analysis of 3,301 ICU admissions with respiratory failure admitted to 41 U.S. Intensive Care Units from 2015-19. Independent external validation on 1,175 similar ICU Admissions using identical entry criteria from Barnes Jewish Hospital (BJH), Washington University from 2016-2019.Main Outcomes TACS was created with 16 readily available predictive variables for risk assessment of hospital mortality 24 hours after ICU Admission and the need for prolonged assisted mechanical ventilation (PAMV) (> 96 hours) at 24- and 48-hours post ICU admission.Results TACS achieved an Area Under the Curve (AUC) for hospital mortality after 24 hours of 0.80 in the development dataset; 0.81 in the internal validation dataset. At a probability of 50% hospital mortality, positive predictive value (PPV) was 0.55, negative predictive value (NPV) 0.89; sensitivity 22%, specificity 97%.For PAMV after 24 hours, the AUC was 0.84 in the development dataset, 0.81 in the validation dataset. For PAMV after 48 hours, the AUC was 0.82 in the development dataset, 0.78 in the validation dataset.In the external validation the AUC for TACS was 0.76 +/- 0.024. We launched a website that is scaled for mobile device use (https://covid19score.azurewebsites.net/) that provides open access to a user-friendly TACS Calculator for all predictions. We also designed a voluntary TACS Registry for collection of data and outcomes on ICU Admissions with COVID-19.Conclusions and Relevance Toward a COVID-19 score is a starting point for an epidemic specific triage assessment that could be used to evaluate various approaches to treatment. The TACS Registry provides the ability to establish a respiratory specific outcomes database that can be used to create a triage approach for future such pandemics.Question Can a rapid epidemic specific risk assessment severity score and data and outcome repository be constructed in the midst of a pandemic.Findings Using development and validation datasets with ICU admissions similar to those developing COVID-19, developed an initial Toward a COVID-19 Score that could be used to compare various treatment approaches. Also launched an online facilitated data collection and outcome assessment registry for collection of a pandemic specific database so a new triage score could be created for use in the next pandemic.Meaning In the midst of a pandemic rapid development of an epidemic specific triage score and a data registry for the creation of a new score for use in future pandemics appears feasible.Competing Interest StatementThe authors have declared no competing interest.Funding StatementSupported in part by The Gordon and Betty Moore Foundation and Washington UniversityAuthor DeclarationsAll relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.YesAll necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe full equations are published in the manuscript. The accompanying website and registry are open to all users. https://covid19score.azurewebsites.net/